Fellowship · Seattle, WA
Sponsored by University of Washington School of Medicine
Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization.
Lancet (London, England) · 2024 · 416 citations · Jon Mosser
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
The New England journal of medicine · 2022 · 868 citations · William Muller
Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19.
JAMA · 2021 · 651 citations · Vijaya Soma
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
MMWR. Morbidity and mortality weekly report · 2024 · 183 citations · Janet Englund, Danielle Zerr
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
The Lancet. Child & adolescent health · 2023 · 248 citations · William Muller
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.
The New England journal of medicine · 2023 · 218 citations · William Muller
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022).
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024 · 189 citations · William Muller
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19.
Cell · 2021 · 549 citations · Caleb Stokes